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Measurement of the global burden of malaria is diﬃ  cult, 
because many deaths from malaria occur outside the 
health-care system and other infections might be 
misdiagnosed as malaria unless a diagnostic test is done. 
However, there is general agreement that a substantial 
reduction in both deaths from malaria and cases has 
occurred during the past decade.1,2 WHO estimates that 
between 2000 and 2015, the annual incidence of malaria 
cases fell by 37% and that the malaria mortality rate fell 
by 60%.3 These reductions have been achieved largely 
through scale-up of insecticide-treated bednets and 
provision of prompt access to eﬀ ective treatment. Can 
even better results be obtained from more of the same? 
WHO estimated that in 2015, about 68% of individuals 
at risk from malaria slept under an insecticide-treated 
bednet; this is probably a generous estimate, which might 
than in a meta-analysis6 that included 423 patients 
who received pegylated interferon plus ribavirin. 
Despite the small number of patients included in 
Abergel and colleagues’ study (mainly because of 
the low frequency of HCV genotype 5 in Europe), 
their study represents the first strong evidence 
that sofosbuvir plus ledipasvir is effective for the 
treatment of HCV genotype 5 infection and should 
therefore be considered as a first-line option for 
treating HCV in this setting.
Abergel and colleagues detected no diﬀ erences in 
SVR with respect to the presence of liver cirrhosis or 
previous treatment experience. Nonetheless, reduced 
SVR was reported for patients with the IL28B TT 
genotype (a genetic marker that was associated with 
a low probability of treatment response during the era 
of interferon treatment for HCV).7 The two patients 
who did not achieve SVR both had the IL28B TT 
genotype. SVR for patients with IL28B TT genotype 
was 50% (achieved by two of four patients). This 
result agrees with the ﬁ ndings of a clinical trial by 
Feld and colleagues, who assessed a new combination 
consisting of sofosbuvir plus velpatasvir once per 
day for 12 weeks.8 Among the 35 patients with HCV 
genotype 5 infection recruited to the study, just one 
patient (who had the IL28B TT genotype) did not 
achieve SVR, and SVR in patients with the IL28B TT 
genotype (two [67%] of three patients) was similar 
to that reported by Abergel and colleagues. Because 
of the small numbers of patients included in both 
studies, no association can be established between 
the IL28B TT genotype and reduced SVR in patients 
with HCV genotype 5 infection who are receiving 
interferon-free regimens. Nevertheless, these results 
show that studies to assess this possible association 
will be important for the optimisation of treatment 
for patients with HCV genotype 5 infection and the 
IL28B TT genotype. These ﬁ ndings could also reopen 
the debate about the need to establish IL28B as a 
predictive factor in the interferon-free era. The fact 
that HCV genotype 5 does not represent a major 
health problem in high-income countries should not 
preclude larger clinical trials being done to assess the 
eﬃ  cacy of interferon-free combinations in this subset 
of patients. Meanwhile, the combination of sofosbuvir 
and ledipasvir represents a substantial advance for the 
treatment of patients with HCV genotype 5 infection.
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not account for intermittent use of nets, and additionally 
only few cases received treatment with artemisinin 
combination therapy. Thus, further scale-up of these 
interventions is needed.
In the Lancet Infectious Diseases, Jamie Griﬃ  n and 
colleagues4 used a well established model of malaria 
transmission5,6 that accounts for increasing population 
size to predict what would happen if coverage of 
established interventions was increased to 80% or 90% 
with or without the addition of rectal artesunate. The 
model accounted for treatment of cases of severe malaria, 
and expansion of seasonal malaria chemoprevention to 
additional areas where it has not been recommended 
because suitable drugs are not available. Finally, 
they predicted what would happen if the status quo 
of coverage is maintained or allowed to fall back to 
the 2006 level. If the current level of coverage with 
insecticide-treated bednets and artemisinin combination 
therapy is sustained they predicted that the incidence 
of malaria would increase by 21% (95% CrI 18–23 ) and 
malaria mortality by 11% (7–16) between 2015 and 
2030 due to population-level loss of immunity caused 
by successful reduction in the incidence of malaria 
during the previous years. With the scaling up of existing 
interventions to 90%, adoption of immediate treatment 
of severe malaria with rectal artesunate, and expansion 
of seasonal malaria chemoprevention they estimate 
that by 2030, malaria incidence would be reduced by 
74% (95% CrI 70–77) and malaria mortality by 81% 
(76–87) preventing an estimated 3·37 billion cases 
(95% CrI 2·37 billion–4·33 billion) and 11·5 million deaths 
(4·6 million–16·0 million) over the 15-year period. 
However, an important issue not covered by Griﬃ  n 
and colleagues in this Article4 is the cost of scale-up. 
As coverage improves, extending it will become more 
diﬃ  cult and costly because access will be needed to 
communities living in remote areas or those who are 
suspicious of the formal health system and prefer to 
seek treatment elsewhere. Increasing coverage from 
60% to 90% cannot be assumed to be half the cost 
of increasing coverage from 0% to 60%. Additionally, 
some communities are likely to be more receptive of one 
intervention than another and obtaining their views will 
be an important requisite to achieving very high coverage 
levels. 
Novel interventions for the control of malaria are being 
developed and some diﬃ  cult decisions will be needed to 
determine how to balance investment in the deployment 
of these new interventions with eﬀ orts to further scale-up 
existing methods to very high levels of coverage. Use of 
models that include a range of costs for each intervention, 
old and new, could help guide the best approach in 
speciﬁ c epidemiological situations, as has been shown in 
investigations of how best to deploy the malaria vaccine 
RTS,S/AS01.7
WHO has published a technical report that sets out the 
strategy for malaria control from 2016 to 2030.8 This 
report lists targets for reducing malaria cases and deaths 
from 2015 levels, by 40% in 2020, 75% in 2025, and 90% 
in 2030 with 10, 20, and 35 countries achieving malaria 
elimination by these dates. The modelling undertaken 
by Griﬃ  n and colleagues4 suggests that these goals are 
not unrealistic, but this is the case only if they are not 
derailed by the spread of high-level resistance to drugs 
and insecticides, a supposition that cannot be assumed 
and that is not included in the model. Therefore, while 
strenuous eﬀ orts to scale-up existing interventions 
continue, research must continue for the development 
of new insec ticides and antimalarial drugs, and on the 
develop ment of vaccines and novel vector-control 
methods, which will almost certainly be needed before 
malaria is ﬁ nally vanquished. 
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